Highlights:
- SNT-9465 is a next-generation topical anti-fibrotic drug developed for the treatment of skin scarring.
- Initial phase of the trial will observe the safety and tolerability of SNT-9465 in healthy participants with skin biopsies to measure drug concentration and enzyme inhibition.
- Potential for SNT-9465 to address unmet need for patients with hypertrophic scars who rely on laser therapy & painful steroid injections.
- Reinforces Syntara’s position as a drug development company with multiple clinical trials of first-in-class drugs underway in high value commercial opportunities.
Syntara Limited (ASX:SNT), a clinical-stage drug development company, is pleased to announce the first participant has been dosed in the Phase 1a/b clinical trial for its topical pan-lysyl oxidase inhibitor SNT-9465, developed for the treatment of hypertrophic scars.
The trial, which commenced dosing at Linear (Joondalup Clinical Trial Centre), Perth, Western Australia, will initially study the drug’s safety and tolerability in healthy participants. The Phase 1a study will determine the optimal dose for complete lysyl oxidase inhibition and will be followed by an open label Phase 1b extension designed to assess improvements in appearance and composition of hypertrophic scars after three months daily treatment.
The results of the trial, expected in H1 2026, will support an FDA Investigational New Drug (IND) application, paving the way for a global development program with the potential to deliver the first approved pharmacological treatment for skin scarring.
Syntara CEO, Gary Phillips stated: “Our discussions with clinicians and global key opinion leaders in scar treatment have highlighted a significant unmet need for patients. Current standard of care includes costly laser therapy or painful steroid injections, requiring multiple treatments for only small incremental improvements. Daily topical treatment with SNT-9465 has the potential to provide profound patient benefits with a non-invasive treatment and without the need for repeat clinical visits.”
